Previous 10 | Next 10 |
Bioavailability of MELT-210 Compares Favorably to Reference Drug Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing novel approaches for procedural sedation and analgesia, today announced top-line results of its phase 1 pharmacokinetics (PK) study...
Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic‑focused healthcare company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will participate in the B. Riley Securities’ Annual Neuro & Ophthalmology Investor Confer...
Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic-focused healthcare company, today announced that it will release its financial results for the first quarter ended March 31, 2022, on Thursday, May 5, 2022, after the market close. The Company will also post its first quarter Letter to S...
Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic-focused healthcare company, today announced the appointments of Perry J. Sternberg and Marty Makary, M.D., M.P.H. to the Company’s Board of Directors, effective immediately. The Company also announced that Robert J. Kammer has res...
The following slide deck was published by Harrow Health, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Harrow Health, Inc. 2021 Q4 - Results - Earnings Call Presentation
Harrow Health, Inc. (HROW) Q4 2021 Earnings Conference Call March 10, 2022 4:45 PM ET Company Participants Jamie Webb – Director-Communications and Investor Relations Mark L. Baum – Chief Executive Officer Andrew Boll – Chief Financial Officer Conference Call Participants...
Harrow Health press release (NASDAQ:HROW): Q4 GAAP EPS of -$0.27 misses by $0.23. Revenue of $20.2M (+38.4% Y/Y) beats by $0.84M. For further details see: Harrow Health GAAP EPS of -$0.27 misses by $0.23, revenue of $20.2M beats by $0.84M
Sixth Consecutive Quarter of Record Revenues Highlights for Fourth Quarter 2021: Record revenues of $20.2 million, a 38% increase compared with $14.6 million for the prior‑year quarter; Gross profit was a record $15.1 million, a 42% increase compared with $10.7 ...
Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing first‑in‑class medicines for sedation and analgesia, today announced the addition of Brad Osborne as Chief Financial Officer. Osborne brings 20 years of extensive finance and accounting experien...
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2021, on Thursday, March 10, 2022, after the market close. The Company will also post its fo...
News, Short Squeeze, Breakout and More Instantly...
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that its management team would attend the 2024 American Society of Retina Specialists (ASRS) Annual Meeting, taking place in Stockholm, Sweden, from July 17-20, 2024. The ASRS Annual Meeting brings tog...
Contract Enhances Purchasing Power for 340B Prime Vendor Program (PVP) Participants; Aligns with Harrow’s Mission to Make Its Products Accessible and Affordable Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that as of July 1, 2024, ...